RxDoctor Payments DataLook up a doctor →

Francesca van Sant

Nurse Practitioner · Bethesda, MDNPI 1174033500

Payments from drug & device makers

$15,554in general payments, 2019–2025

Across 404 payments — averaging $38.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Novartis$2K
  • Fennec Pharmaceuticals, Inc.$2K
  • Johnson & Johnson$1K
  • Merck$478
  • Pfizer$378
  • plus $6K from 54 others

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie23$2,804
Novartis56$2,285
Fennec Pharmaceuticals, Inc.10$1,937
Johnson & Johnson(2 entities)50$1,445
Merck20$478
Pfizer15$378
Daiichi Sankyo Inc.13$336
Rigel Pharmaceuticals, Inc.4$271
Takeda Pharmaceuticals U.S.A., Inc.10$267
Astellas Pharma US Inc8$261
Seagen Inc.13$257
Tempus AI, Inc3$249
Exelixis Inc.7$241
Bristol Myers Squibb9$237
Incyte Corporation7$236
Amgen10$229
Genentech USA, Inc.6$214
AstraZeneca9$213
Sanofi8$185
E.r. Squibb & Sons, L.L.C.5$183
Beigene USA, Inc.3$168
Bayer7$165
Eisai Inc.8$161
AVEO Pharmaceuticals, Inc.5$151
Pharmacyclics LLC, An Abbvie Company7$148
GSK6$132
Regeneron Healthcare Solutions, Inc.4$102
Pharmacosmos Therapeutics Inc.4$101
Genmab U.S., Inc.3$97
Lilly USA, LLC6$96
Taiho Oncology, Inc.4$92
Janssen Scientific Affairs, LLC1$83
ADC Therapeutics America, Inc.3$72
Array Biopharma Inc3$66
Global Blood Therapeutics, Inc.3$66
Morphosys, US Inc.3$64
Myovant Sciences Inc.3$62
Syndax Pharmaceuticals, Inc.2$62
Ipsen Biopharmaceuticals, Inc3$61
Mirati Therapeutics, Inc.2$54
Pharmaessentia USA Corporation2$52
Tersera Therapeutics LLC2$49
Gilead(2 entities)2$48
EMD Serono, Inc.2$45
Stemline Therapeutics Inc.2$44
Heron Therapeutics, Inc.3$43
Deciphera Pharmaceuticals Inc.2$42
Kyowa Kirin, Inc.2$41
Beone Medicines USA, Inc.1$32
Acrotech Biopharma Inc.2$32
Caris MPI, Inc.1$30
Blueprint Medicines Corporation1$30
Invivyd Inc1$30
Sobi, Inc1$29
EUSA Pharma (US) LLC1$28
Novocure Inc.1$28
Iovance Biotherapeutics, Inc.1$25
Myriad Genetic Laboratories, Inc.1$24
Mylan Institutional Inc.1$23
Dova Pharmaceuticals1$22

How this compares

$15,554 in reported general payments places this provider in the 95th percentile of 1,562 nurse practitioner providers in Maryland.

See all nurse practitioner providers in Maryland →

Medicare billing

Part B allowed, 2024
$71,511
Medicare patients
164
Services billed
2,081

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other nurse practitioner in Bethesda

See the full list for Maryland →

Where these figures come from

Is this you, or does something look wrong? →